Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease.
BACKGROUND
Dimebon is a retired non-selective antihistamine drug currently being investigated as a therapeutic agent for the treatment of Alzheimer's disease (AD). Results from several completed clinical trials are mixed and contradictory. Proper interpretations of these clinical observations, as well as future development of dimebon in AD treatment are complicated by the lack of concrete information on the mechanisms by which dimebon might benefit AD.


RESULTS
The present studies are designed specifically to assess whether dimebon might modulate β-amyloid (Aβ)-mediated responses which are central to the development and progression of AD dementia. We found that dimebon is bioavailable in the brains of mice following oral administration. AD mice chronically treated with dimebon exhibited a trend of improvement in spatial memory function without affecting the levels of total Aβ as well as soluble oligomeric Aβ in the brain. The same trend of behavior improvement is also seen in wild type animals chronically treated with dimebon.


CONCLUSIONS
Collectively, our preclinical studies using the TgCRND8 AD mouse model demonstrated that dimebon might have some beneficial effect in improving cognitive function independent of Alzheimer's disease-type Aβ-related mechanisms or global energy metabolism in the brain. Observations from our study and others suggesting dimebon might improve cognition in wild type mice and rats raises the possibility that dimebon might be able to benefit cognitive function in patients with other neurodegenerative disorders, such as Huntington's disease, or in the aging population. Additional studies will be necessary to clarify the mechanisms by which dimebon might directly or indirectly benefit cognitive function.
Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 USA. giulio.pasinetti@mssm.edu.
Jun
J
Wang
Mario G
MG
Ferruzzi
Merina
M
Varghese
Xianjuan
X
Qian
Alice
A
Cheng
Mathew
M
Xie
Wei
W
Zhao
Lap
L
Ho
Giulio M
GM
Pasinetti
Ann N Y Acad Sci. 2003 May;993:334-44; discussion 345-9
12853325
Neuroscience. 2008 Feb 6;151(3):745-9
18155846
Biochem Pharmacol. 2009 Oct 15;78(8):1035-42
19549510
J Neurosci. 2008 Jun 18;28(25):6388-92
18562609
Arch Neurol. 2010 Feb;67(2):154-60
20142523
Nature. 2006 Mar 16;440(7082):352-7
16541076
Mol Neurodegener. 2008 Oct 21;3:15
18939977
Neurochem Int. 2002 Nov;41(5):345-52
12176077
J Neurosci. 2007 Mar 14;27(11):2866-75
17360908
J Biol Chem. 2001 Jun 15;276(24):21562-70
11279122
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3563-71
19748323
Arch Neurol. 1988 Aug;45(8):836-40
3395256
J Neurosci Methods. 1984 May;11(1):47-60
6471907
Bull Exp Biol Med. 2001 Nov;132(5):1079-83
11865327
Nat Med. 2008 Aug;14(8):837-42
18568035
FASEB J. 2005 Apr;19(6):659-61
15650008
Nature. 2002 Apr 4;416(6880):535-9
11932745
J Alzheimers Dis. 2010;21(2):389-402
20555134
J Pharmacol Exp Ther. 2010 Jun;333(3):748-57
20194526
J Clin Invest. 2007 Nov;117(11):3393-402
17965777
Anal Biochem. 1973 Aug;54(2):477-83
4146785
Proc Natl Acad Sci U S A. 1973 Sep;70(9):2534-8
4354855
Ann N Y Acad Sci. 2001 Jun;939:425-35
11462798
Lancet. 2008 Jul 19;372(9634):207-15
18640457
Science. 1996 Oct 4;274(5284):99-102
8810256
Mol Neurodegener. 2009 Dec 17;4:51
20017949
Ann Neurol. 2005 May;57(5):695-703
15852400
Biochem Soc Trans. 2002 Aug;30(4):552-7
12196135
J Neurosci. 2001 Jan 15;21(2):372-81
11160418